▁Bre 10.375
ast 6.74609375
▁cancer 7.609375
▁is 6.703125
▁a 1.7890625
▁complex 6.05859375
▁and 2.6796875
▁potentially 4.9296875
▁life 2.267578125
- 0.393798828125
th 0.058837890625
re 0.007244110107421875
aten 0.185546875
ing 0.01345062255859375
▁disease 1.3203125
▁that 1.7255859375
▁affect 2.931640625
s 0.032135009765625
▁both 4.31640625
▁women 3.359375
▁and 0.181396484375
▁men 0.11724853515625
. 1.2080078125
▁Vari 7.23828125
ous 0.14453125
▁critical 9.015625
▁factors 2.705078125
▁contribute 3.75390625
▁to 0.155517578125
▁its 2.884765625
▁development 1.310546875
, 1.1142578125
▁including 1.2802734375
▁her 4.7734375
ed 1.0009765625
ity 0.0212249755859375
, 0.305908203125
▁dise 8.7578125
ases 0.00965118408203125
▁of 2.828125
▁the 0.7890625
▁m 4.9140625
amm 0.5546875
ary 0.006450653076171875
▁g 0.266357421875
lands 1.0849609375
, 0.299072265625
▁and 2.01953125
▁h 2.994140625
orm 0.003833770751953125
onal 0.1331787109375
▁factors 2.310546875
. 0.41162109375
▁Det 9.1015625
ect 1.5595703125
ing 0.446044921875
▁early 3.13671875
▁met 7.44140625
ast 0.3623046875
asis 2.39453125
▁and 2.376953125
▁determ 5.4140625
ining 0.018829345703125
▁the 0.74609375
▁ag 4.68359375
gress 0.03326416015625
iveness 0.20068359375
▁of 0.15625
▁the 0.89501953125
▁cancer 1.7177734375
▁type 8.6484375
▁are 1.25
▁cru 2.57421875
cial 0.01129150390625
▁for 0.9775390625
▁successful 3.20703125
▁treatment 0.57861328125
▁and 2.080078125
▁improved 5.0078125
▁patient 2.423828125
▁out 1.3466796875
comes 0.045654296875
. 0.09600830078125
<0x0A> 1.44921875
First 6.94921875
ly 3.255859375
, 0.044097900390625
▁her 6.4140625
ed 0.478759765625
ity 0.01229095458984375
▁plays 1.7978515625
▁a 0.362060546875
▁significant 1.8515625
▁role 0.048248291015625
▁in 0.2196044921875
▁breast 2.35546875
▁cancer 0.0287322998046875
▁development 0.9228515625
. 0.65966796875
▁C 4.6015625
ertain 0.13525390625
▁gen 0.595703125
etic 1.7314453125
▁mut 1.1787109375
ations 0.008758544921875
, 2.0390625
▁such 0.8671875
▁as 0.00345611572265625
▁BR 0.72265625
CA 0.0018291473388671875
1 0.25732421875
▁and 0.37353515625
▁BR 0.057220458984375
CA 0.003414154052734375
2 0.0094757080078125
, 0.193603515625
▁can 2.513671875
▁be 2.638671875
▁inherited 0.9609375
▁from 1.2021484375
▁parents 1.7607421875
▁and 1.5849609375
▁increase 2.736328125
▁the 0.3505859375
▁risk 0.23876953125
▁of 0.0679931640625
▁developing 0.85009765625
▁breast 0.391357421875
▁cancer 0.07977294921875
. 0.488525390625
▁Ind 6.16796875
ividual 0.01708984375
s 0.09954833984375
▁with 0.7080078125
▁a 0.87109375
▁family 1.4931640625
▁history 0.01410675048828125
▁of 0.033050537109375
▁breast 0.220947265625
▁or 3.466796875
▁o 0.1375732421875
var 0.0004987716674804688
ian 0.00011074542999267578
▁cancer 0.0333251953125
▁need 6.703125
▁to 0.083251953125
▁be 0.79541015625
▁more 2.345703125
▁vig 1.580078125
il 0.00017440319061279297
ant 0.0048980712890625
▁about 0.6640625
▁regular 3.859375
▁screen 1.1591796875
ings 0.88037109375
▁and 0.7763671875
▁may 4.3984375
▁consider 3.71484375
▁gen 2.25390625
etic 0.003864288330078125
▁testing 0.39892578125
▁to 1.0888671875
▁assess 2.8359375
▁their 0.5888671875
▁risk 0.52197265625
. 1.419921875
<0x0A> 0.60595703125
Second 0.93603515625
ly 0.043792724609375
, 0.0015773773193359375
▁dise 2.328125
ases 0.0004329681396484375
▁of 0.06982421875
▁the 0.01190948486328125
▁m 0.0240325927734375
amm 0.0003581047058105469
ary 0.00011980533599853516
▁g 0.0035800933837890625
lands 0.06787109375
▁can 1.1103515625
▁contribute 1.6923828125
▁to 0.04010009765625
▁the 0.57958984375
▁development 0.1790771484375
▁of 0.055328369140625
▁breast 0.1759033203125
▁cancer 0.011810302734375
. 0.212158203125
▁Cond 4.5859375
itions 0.00437164306640625
▁such 0.39990234375
▁as 0.0014276504516601562
▁at 5.08203125
yp 0.29638671875
ical 0.017181396484375
▁hyper 0.1072998046875
pl 0.0181732177734375
asia 0.005435943603515625
▁and 1.4736328125
▁lo 2.423828125
b 0.003753662109375
ular 0.0008535385131835938
▁car 0.2685546875
cin 9.191036224365234e-05
oma 0.0011968612670898438
▁in 0.0304107666015625
▁situ 0.052276611328125
▁can 1.83203125
▁increase 1.8603515625
▁the 0.310302734375
▁lik 3.654296875
elihood 0.0014009475708007812
▁of 0.045440673828125
▁developing 0.705078125
▁invas 2.5
ive 0.00013208389282226562
▁breast 0.45751953125
▁cancer 0.035369873046875
. 0.525390625
▁Additionally 3.8671875
, 0.0011005401611328125
▁individuals 5.55859375
▁who 1.40625
▁have 0.5693359375
▁previously 4.75
▁had 1.2392578125
▁breast 0.587890625
▁cancer 0.2174072265625
▁or 1.4228515625
▁ben 6.9765625
ign 1.609325408935547e-05
▁breast 0.2486572265625
▁dise 2.87109375
ases 0.0008058547973632812
▁like 4.1328125
▁fib 0.416259765625
roc 1.171875
yst 0.00189971923828125
ic 0.0015211105346679688
▁changes 1.94140625
▁need 5.68359375
▁to 0.020233154296875
▁be 0.262451171875
▁monitor 3.16796875
ed 5.161762237548828e-05
▁more 1.998046875
▁closely 0.306640625
▁to 2.037109375
▁detect 0.86572265625
▁any 1.5126953125
▁potential 3.052734375
▁rec 1.466796875
urrence 0.285400390625
▁or 2.12109375
▁new 2.0625
▁m 4.515625
align 0.1754150390625
an 0.47412109375
cies 4.172325134277344e-05
. 0.09814453125
<0x0A> 0.10650634765625
H 1.6787109375
orm 0.0021343231201171875
onal 0.1304931640625
▁factors 0.0654296875
▁also 1.4306640625
▁play 0.38916015625
▁a 0.155029296875
▁role 0.916015625
▁in 0.019989013671875
▁breast 0.96240234375
▁cancer 0.0171356201171875
. 3.046875
▁Est 2.302734375
ro 0.1614990234375
gen 3.7789344787597656e-05
▁and 0.9287109375
▁pro 0.046783447265625
g 0.01200103759765625
ester 3.254413604736328e-05
one 0.0009446144104003906
, 2.412109375
▁female 6.66796875
▁sex 0.5546875
▁h 0.04803466796875
orm 5.125999450683594e-06
ones 0.00218963623046875
, 0.36669921875
▁can 1.482421875
▁stim 1.8173828125
ulate 0.00015723705291748047
▁the 0.51513671875
▁growth 0.3828125
▁of 0.239501953125
▁certain 3.9375
▁breast 0.9267578125
▁cancer 1.1640625
▁cells 0.1673583984375
. 0.646484375
▁Women 3.72265625
▁who 0.4990234375
▁start 6.09375
▁men 1.0947265625
stru 0.413330078125
ating 0.06549072265625
▁early 3.0234375
, 2.443359375
▁experience 3.68359375
▁late 6.02734375
▁men 0.70751953125
op 0.0697021484375
ause 0.00473785400390625
, 0.1651611328125
▁or 0.2445068359375
▁have 0.82275390625
▁never 4.046875
▁been 1.3310546875
▁pre 0.217041015625
gn 0.00010097026824951172
ant 4.184246063232422e-05
▁are 0.79345703125
▁at 0.5556640625
▁a 1.3955078125
▁higher 0.360595703125
▁risk 0.0086822509765625
▁of 0.295654296875
▁developing 0.2257080078125
▁breast 0.20361328125
▁cancer 0.00980377197265625
▁due 2.9609375
▁to 0.002750396728515625
▁prolong 6.17578125
ed 0.0014486312866210938
▁expos 0.3125
ure 0.001613616943359375
▁to 0.032501220703125
▁these 0.92333984375
▁h 0.298828125
orm 3.5762786865234375e-07
ones 0.04669189453125
. 0.0771484375
▁H 4.02734375
orm 0.0311431884765625
one 1.00390625
▁replacement 0.63037109375
▁ther 0.0142822265625
apy 0.07891845703125
▁after 4.59375
▁men 0.1888427734375
op 0.0009245872497558594
ause 0.0028781890869140625
▁can 0.6396484375
▁also 1.521484375
▁increase 1.1923828125
▁the 0.3251953125
▁risk 0.10711669921875
, 4.59375
▁and 2.6953125
▁therefore 3.873046875
, 1.6396484375
▁careful 6.609375
▁consideration 2.478515625
▁should 1.7021484375
▁be 0.0100250244140625
▁given 0.366943359375
▁to 0.246337890625
▁its 4.515625
▁use 0.34130859375
. 0.58056640625
<0x0A> 0.1341552734375
Det 3.19140625
ect 0.370849609375
ing 0.00496673583984375
▁early 1.80078125
▁met 0.7890625
ast 0.00011563301086425781
asis 0.06280517578125
▁is 2.658203125
▁cru 1.4375
cial 0.0012197494506835938
▁as 5.94921875
▁it 0.79248046875
▁greatly 5.0859375
▁impact 1.294921875
s 0.0015726089477539062
▁treatment 2.513671875
▁out 1.5166015625
comes 0.0004057884216308594
. 0.72509765625
▁Met 3.05859375
ast 0.0036182403564453125
asis 0.6044921875
▁refers 1.8125
▁to 0.00113677978515625
▁the 0.1260986328125
▁spread 0.357421875
▁of 0.0633544921875
▁cancer 0.1951904296875
▁cells 0.79638671875
▁from 0.56787109375
▁the 0.46240234375
▁primary 0.316162109375
▁tum 0.4736328125
or 0.2437744140625
▁to 0.320556640625
▁other 0.323974609375
▁parts 1.146484375
▁of 0.001926422119140625
▁the 0.00244140625
▁body 0.00627899169921875
. 0.5791015625
▁Early 1.8125
▁detection 0.673828125
▁of 1.12890625
▁met 0.4296875
ast 0.00017786026000976562
asis 0.28955078125
▁allows 1.5673828125
▁medical 4.55078125
▁profession 0.344482421875
als 1.0728836059570312e-06
▁to 0.0308990478515625
▁interven 3.56640625
e 1.9073486328125e-05
▁prompt 5.0390625
ly 0.00015878677368164062
▁and 0.73974609375
▁implement 5.97265625
▁appropriate 2.677734375
▁treatment 0.464111328125
▁strateg 1.9013671875
ies 2.0265579223632812e-05
. 0.74169921875
▁Method 8.640625
s 0.004688262939453125
▁used 2.548828125
▁to 0.261962890625
▁determine 4.66796875
▁met 1.9091796875
ast 0.0002803802490234375
asis 0.27099609375
▁include 0.392578125
▁imag 1.462890625
ing 0.00286102294921875
▁techniques 1.91015625
▁like 1.5478515625
▁CT 1.6376953125
▁sc 0.7880859375
ans 0.12890625
, 0.861328125
▁P 2.23046875
ET 0.0004439353942871094
▁sc 0.07244873046875
ans 0.00431060791015625
, 0.057281494140625
▁and 0.37646484375
▁b 3.51171875
one 0.0016908645629882812
▁sc 0.1187744140625
ans 0.0255584716796875
, 1.0556640625
▁which 2.337890625
▁can 1.3525390625
▁identify 2.736328125
▁the 1.69921875
▁presence 1.302734375
▁of 0.13427734375
▁cancer 1.060546875
▁in 2.17578125
▁distant 2.498046875
▁org 1.4375
ans 6.198883056640625e-06
. 0.84619140625
<0x0A> 0.8271484375
Det 1.6650390625
erm 0.5625
ining 0.0196685791015625
▁the 0.2239990234375
▁ag 0.1573486328125
gress 0.0006957054138183594
iveness 0.0027370452880859375
▁of 0.0250244140625
▁breast 2.697265625
▁cancer 0.0079345703125
▁is 0.6787109375
▁essential 2.552734375
▁for 0.638671875
▁determ 1.9111328125
ining 0.00018775463104248047
▁optimal 4.515625
▁treatment 0.11859130859375
▁plans 3.3515625
. 0.5283203125
▁Vari 3.513671875
ous 0.01403045654296875
▁factors 0.374755859375
, 1.4921875
▁such 0.57763671875
▁as 0.0014257431030273438
▁tum 1.4697265625
or 0.005046844482421875
▁size 0.390380859375
, 0.2685546875
▁grade 2.630859375
, 0.1986083984375
▁and 0.33203125
▁h 2.669921875
orm 0.00131988525390625
one 0.453857421875
▁re 0.06689453125
ceptor 0.462646484375
▁status 0.049163818359375
, 0.27294921875
▁help 4.2421875
▁assess 3.9296875
▁the 0.42041015625
▁ag 1.9189453125
gress 0.003143310546875
iveness 0.007228851318359375
▁of 0.07122802734375
▁the 0.703125
▁cancer 0.418212890625
▁type 1.615234375
. 0.2322998046875
▁Additionally 4.28125
, 0.00028061866760253906
▁gen 4.47265625
etic 0.045440673828125
▁profil 4.09375
ing 5.269050598144531e-05
▁can 1.0625
▁provide 2.63671875
▁information 2.4296875
▁about 0.50927734375
▁specific 4.3671875
▁gene 3.42578125
▁mut 0.14794921875
ations 0.00513458251953125
▁that 0.87060546875
▁may 1.388671875
▁influence 2.349609375
▁the 0.61181640625
▁behavior 4.73828125
▁of 0.2154541015625
▁the 0.4052734375
▁cancer 0.3515625
▁cells 1.1748046875
. 0.313720703125
▁This 2.603515625
▁information 0.8583984375
▁allows 2.79296875
▁health 3.228515625
care 0.250732421875
▁prov 1.36328125
iders 5.364418029785156e-06
▁to 0.01178741455078125
▁tail 2.17578125
or 0.00017058849334716797
▁treatment 0.5546875
▁options 2.513671875
▁to 0.75732421875
▁individual 2.19140625
▁patients 0.65185546875
, 1.771484375
▁maxim 3.994140625
izing 0.4169921875
▁their 1.244140625
▁ch 0.56787109375
ances 4.5299530029296875e-05
▁of 0.1461181640625
▁successful 2.837890625
▁out 0.90576171875
comes 0.0003616809844970703
. 0.1422119140625
<0x0A> 0.035400390625
In 2.99609375
▁conclusion 0.80517578125
, 0.0009088516235351562
▁understanding 5.91015625
▁the 0.25
▁critical 5.80859375
▁factors 0.17578125
▁that 0.455078125
▁contribute 0.412109375
▁to 0.002468109130859375
▁breast 1.51953125
▁cancer 0.0011472702026367188
▁development 0.252197265625
, 0.7041015625
▁including 1.900390625
▁her 0.4482421875
ed 0.030029296875
ity 0.00017452239990234375
, 0.08349609375
▁dise 0.438232421875
ases 3.7550926208496094e-05
▁of 0.01210784912109375
▁the 0.004070281982421875
▁m 0.001461029052734375
amm 0.0005917549133300781
ary 4.565715789794922e-05
▁g 0.0008692741394042969
lands 0.007297515869140625
, 0.0256805419921875
▁and 0.07342529296875
▁h 0.0115203857421875
orm 4.76837158203125e-07
onal 0.0254058837890625
▁factors 0.0025787353515625
, 0.08526611328125
▁is 0.517578125
▁vital 3.025390625
▁for 0.382080078125
▁effective 2.56640625
▁prevent 2.26171875
ion 0.07977294921875
▁and 0.375
▁early 1.8564453125
▁detection 0.1500244140625
. 0.88427734375
▁Early 2.0859375
▁identification 4.66796875
▁of 0.465087890625
▁met 0.30615234375
ast 7.355213165283203e-05
asis 0.0989990234375
▁and 0.455078125
▁determ 0.340576171875
ining 0.1287841796875
▁the 0.031890869140625
▁ag 0.027099609375
gress 0.00017726421356201172
iveness 0.0006060600280761719
▁of 0.006465911865234375
▁the 0.2188720703125
▁cancer 0.07977294921875
▁type 0.0487060546875
▁through 6.84765625
▁various 2.716796875
▁methods 2.08203125
▁enable 6.4921875
▁health 1.619140625
care 0.034881591796875
▁profession 0.68896484375
als 3.5762786865234375e-06
▁to 0.0022716522216796875
▁provide 1.7724609375
▁appropriate 2.658203125
▁treatment 0.14208984375
▁strateg 1.1474609375
ies 1.7881393432617188e-06
, 2.787109375
▁thus 4.1796875
▁impro 0.697265625
ving 4.982948303222656e-05
▁patient 0.60302734375
▁pro 7.1953125
gn 0.0010519027709960938
osis 0.349365234375
▁and 0.65869140625
▁quality 2.279296875
▁of 0.008026123046875
▁life 0.0019378662109375
. 0.01432037353515625
